Dataset related to the article "Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis"

This record contains raw data related to the article "Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis" ABSTRACT The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the PCSK9 R46L variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80 [95% confidence interval: 0.70 to 0.91]; p = 0.0011) compared with noncarriers. PCSK9 expression was higher in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells submitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly reduced calcium accumulation.本数据集包含与论文《PCSK9的基因与体外抑制研究及钙化性主动脉瓣狭窄》相关的原始数据。 摘要：研究者旨在探讨PCSK9抑制能否作为钙化性主动脉瓣狭窄（calcific aortic valve stenosis, CAVS）的治疗策略。研究者针对10项研究开展荟萃分析，以明确PCSK9 R46L变异体对钙化性主动脉瓣狭窄的影响；结果显示，与非携带者相比，该变异体携带者的钙化性主动脉瓣狭窄患病率更低（优势比：0.80 [95%置信区间：0.70~0.91]；p=0.0011）。钙化性主动脉瓣狭窄患者的主动脉瓣中PCSK9表达水平高于对照患者。在经成骨诱导培养基培养的人瓣膜间质细胞中，PCSK9水平升高，且PCSK9中和抗体可显著减少钙沉积。